{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.6","upperLimit":"3.5","value":"1.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"}],"units":"Participants"}],"description":"The Kaplan-Meier method will be used to estimate time to progression estimates.\n\nProgression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive oral AZD0530 (saracatinib ) at a dose of 175 mg, once daily, in the absence of disease progression or unacceptable toxicity.\n\nsaracatinib: Given orally","id":"OG000","title":"Arm I"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Up to 5 years","title":"Time to Disease Progression","type":"SECONDARY","unitOfMeasure":"months"}